210 related articles for article (PubMed ID: 31446428)
1. Risk of acute arterial events associated with treatment of inflammatory bowel diseases: nationwide French cohort study.
Kirchgesner J; Nyboe Andersen N; Carrat F; Jess T; Beaugerie L;
Gut; 2020 May; 69(5):852-858. PubMed ID: 31446428
[TBL] [Abstract][Full Text] [Related]
2. Risk of Recurrent Acute Arterial Events Associated With Thiopurines and Anti-Tumor Necrosis Factor in Inflammatory Bowel Diseases.
Dheyriat L; Ward D; Beaugerie L; Jess T; Kirchgesner J
Clin Gastroenterol Hepatol; 2023 Jan; 21(1):164-172.e11. PubMed ID: 35842123
[TBL] [Abstract][Full Text] [Related]
3. Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases.
Kirchgesner J; Lemaitre M; Carrat F; Zureik M; Carbonnel F; Dray-Spira R
Gastroenterology; 2018 Aug; 155(2):337-346.e10. PubMed ID: 29655835
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009-2014.
Kirchgesner J; Lemaitre M; Rudnichi A; Racine A; Zureik M; Carbonnel F; Dray-Spira R
Aliment Pharmacol Ther; 2017 Jan; 45(1):37-49. PubMed ID: 27781286
[TBL] [Abstract][Full Text] [Related]
5. Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study.
Kirchgesner J; Beaugerie L; Carrat F; Andersen NN; Jess T; Schwarzinger M;
Gut; 2018 Jul; 67(7):1261-1268. PubMed ID: 28647686
[TBL] [Abstract][Full Text] [Related]
6. Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.
Cheddani H; Dauchet L; Fumery M; Charpentier C; Marie Bouvier A; Dupas JL; Pariente B; Peyrin-Biroulet L; Savoye G; Gower-Rousseau C
Am J Gastroenterol; 2016 Oct; 111(10):1428-1436. PubMed ID: 27481308
[TBL] [Abstract][Full Text] [Related]
7. Increased risk of pneumonia among patients with inflammatory bowel disease.
Long MD; Martin C; Sandler RS; Kappelman MD
Am J Gastroenterol; 2013 Feb; 108(2):240-8. PubMed ID: 23295276
[TBL] [Abstract][Full Text] [Related]
8. Impact of thiopurines and tumour necrosis factor antagonists on primary sclerosing cholangitis outcomes in patients with inflammatory bowel disease.
Biron A; Beaugerie L; Chazouillères O; Kirchgesner J
Aliment Pharmacol Ther; 2022 Sep; 56(5):857-868. PubMed ID: 35789494
[TBL] [Abstract][Full Text] [Related]
9. Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer.
Scott FI; Mamtani R; Brensinger CM; Haynes K; Chiesa-Fuxench ZC; Zhang J; Chen L; Xie F; Yun H; Osterman MT; Beukelman T; Margolis DJ; Curtis JR; Lewis JD
JAMA Dermatol; 2016 Feb; 152(2):164-72. PubMed ID: 26510126
[TBL] [Abstract][Full Text] [Related]
10. Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease.
Lemaitre M; Kirchgesner J; Rudnichi A; Carrat F; Zureik M; Carbonnel F; Dray-Spira R
JAMA; 2017 Nov; 318(17):1679-1686. PubMed ID: 29114832
[TBL] [Abstract][Full Text] [Related]
11. Timing of Thiopurine or Anti-TNF Initiation Is Associated with the Risk of Major Abdominal Surgery in Crohn's Disease: A Retrospective Cohort Study.
González-Lama Y; Suárez C; González-Partida I; Calvo M; Matallana V; de la Revilla J; Magaz M; Bernardo C; Agudo B; Ibarrola P; Relea L; Arévalo J; Vera MI; Abreu L
J Crohns Colitis; 2016 Jan; 10(1):55-60. PubMed ID: 26520164
[TBL] [Abstract][Full Text] [Related]
12. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.
Beigel F; Steinborn A; Schnitzler F; Tillack C; Breiteneicher S; John JM; Van Steen K; Laubender RP; Göke B; Seiderer J; Brand S; Ochsenkühn T
Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):735-44. PubMed ID: 24788825
[TBL] [Abstract][Full Text] [Related]
13. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study.
Bae JM; Lee HH; Lee BI; Lee KM; Eun SH; Cho ML; Kim JS; Park JM; Cho YS; Lee IS; Kim SW; Choi H; Choi MG
Aliment Pharmacol Ther; 2018 Jul; 48(2):196-205. PubMed ID: 29869804
[TBL] [Abstract][Full Text] [Related]
14. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study.
Casanova MJ; Chaparro M; García-Sánchez V; Nantes O; Leo E; Rojas-Feria M; Jauregui-Amezaga A; García-López S; Huguet JM; Arguelles-Arias F; Aicart M; Marín-Jiménez I; Gómez-García M; Muñoz F; Esteve M; Bujanda L; Cortés X; Tosca J; Pineda JR; Mañosa M; Llaó J; Guardiola J; Pérez-Martínez I; Muñoz C; González-Lama Y; Hinojosa J; Vázquez JM; Martinez-Montiel MP; Rodríguez GE; Pajares R; García-Sepulcre MF; Hernández-Martínez A; Pérez-Calle JL; Beltrán B; Busquets D; Ramos L; Bermejo F; Barrio J; Barreiro-de Acosta M; Roncedo O; Calvet X; Hervías D; Gomollón F; Domínguez-Antonaya M; Alcaín G; Sicilia B; Dueñas C; Gutiérrez A; Lorente-Poyatos R; Domínguez M; Khorrami S; Muñoz C; Taxonera C; Rodríguez-Pérez A; Ponferrada A; Van Domselaar M; Arias-Rivera ML; Merino O; Castro E; Marrero JM; Martín-Arranz M; Botella B; Fernández-Salazar L; Monfort D; Opio V; García-Herola A; Menacho M; Ramírez-de la Piscina P; Ceballos D; Almela P; Navarro-Llavat M; Robles-Alonso V; Vega-López AB; Moraleja I; Novella MT; Castaño-Milla C; Sánchez-Torres A; Benítez JM; Rodríguez C; Castro L; Garrido E; Domènech E; García-Planella E; Gisbert JP
Am J Gastroenterol; 2017 Jan; 112(1):120-131. PubMed ID: 27958281
[TBL] [Abstract][Full Text] [Related]
15. Overall and Comparative Risk of Herpes Zoster With Pharmacotherapy for Inflammatory Bowel Diseases: A Nationwide Cohort Study.
Khan N; Patel D; Trivedi C; Shah Y; Lichtenstein G; Lewis J; Yang YX
Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1919-1927.e3. PubMed ID: 29309905
[TBL] [Abstract][Full Text] [Related]
16. Do Thiopurines Reduce the Risk of Surgery in Elderly Onset Inflammatory Bowel Disease? A 20-Year National Population-Based Cohort Study.
Alexakis C; Saxena S; Chhaya V; Cecil E; Curcin V; Pollok R
Inflamm Bowel Dis; 2017 Apr; 23(4):672-680. PubMed ID: 28151735
[TBL] [Abstract][Full Text] [Related]
17. Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease.
Long MD; Martin C; Sandler RS; Kappelman MD
Aliment Pharmacol Ther; 2013 Feb; 37(4):420-9. PubMed ID: 23240738
[TBL] [Abstract][Full Text] [Related]
18. Anti-Tumour Necrosis Factor Therapy for Inflammatory Bowel Diseases Do Not Impact Serious Infections after Arthroplasty.
Gregory MH; McKinnon A; Stwalley D; Hippensteel KJ; Loftus EV; Ciorba MA; Olsen MA; Deepak P
J Crohns Colitis; 2019 Feb; 13(2):182-188. PubMed ID: 30256926
[TBL] [Abstract][Full Text] [Related]
19. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease.
Long MD; Martin CF; Pipkin CA; Herfarth HH; Sandler RS; Kappelman MD
Gastroenterology; 2012 Aug; 143(2):390-399.e1. PubMed ID: 22584081
[TBL] [Abstract][Full Text] [Related]
20. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease.
Peyrin-Biroulet L; Khosrotehrani K; Carrat F; Bouvier AM; Chevaux JB; Simon T; Carbonnel F; Colombel JF; Dupas JL; Godeberge P; Hugot JP; Lémann M; Nahon S; Sabaté JM; Tucat G; Beaugerie L;
Gastroenterology; 2011 Nov; 141(5):1621-28.e1-5. PubMed ID: 21708105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]